Doxorubicin and NF-Kβ inhibitors increase TRAIL/Apo2L expression in MM cells, but not in normal B cells, which suggests the targeting of TRAIL/Apo2L as a novel therapeutic strategy in MM (104). Here, TNFSF10 is linked to Miyoshi myopathy.